A phase 1 trial of ACT-903 in solid and hematological cancers
Latest Information Update: 02 Jun 2023
At a glance
- Drugs ACT 903 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Alpha Cancer Technologies
- 31 May 2023 According to a Alpha Cancer Technologies media release, the company expect to submit an Investigational New Drug (IND) application for ACT-903 in 2024 and initiate this study next year.
- 23 Sep 2021 New trial record